References
±, anxiety/depression, fatigue, cognitive fatigue
Consolidated Standards of Reporting Trials (CONSORT) flow diagram illustrating the steps of screening, enrollment, assignment, and follow-up of the study participants.Summary of the study schedule at each visit during the clinical trial.Dot plot of individual paired data of the cognitive fatigue domain (assessed using FIS-40) with significant differences. The differences between the values of the cognitive subscale domain are shown. Each point represents the score of each patient. Bars depict group medians. Lines indicate that cognitive scores belong to the same patient. Green lines depict a decrease in the perceived cognitive fatigue score (better cognitive function), and the red lines indicate an increase in the perceived cognitive fatigue score (poor cognitive function) from the baseline as quantified on the Baseline demographic and clinical features for each arm of the study participants.Data are expressed as means ± standard deviation (SD) for continuous variables. In both cases, the non-parametric Mann–Whitney U test was used because the samples were not normally distributed. No significant differences were observed in either case, confirming that both samples were derived from the same population. The Chi-squared test of independence was performed with one degree of freedom, and no significant differences in the proportions were observed, so no variable was considered to exert a different influence depending on the group. Abbreviations: BMI, body mass index; NSAIDs, non-steroidal anti-inflammatory drugs.Changes in the fatigue severity assessed with the FIS-40 score from the baseline to the final assessment (at week 36) in the study participants.Data are expressed as means ± SD. Changes in sleep quality assessed using the PSQI questionnaire from the baseline to the final assessment (week 36).Data are expressed as means ± SD. Changes in the anxiety/depression symptoms assessed through the HADS questionnaire from the baseline to the final assessment (at week 36).Data are expressed as means ± SD. Changes in the health-related quality of life evaluated using the SF-36 questionnaire from the baseline to the final assessment (at week 36).Data are expressed as means ± SD. 